Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
400.3 BRL | +13.59% | +3.17% | +46.81% |
06-03 | Boston Scientific Insider Sold Shares Worth $526,029, According to a Recent SEC Filing | MT |
05-31 | Boston Scientific Insider Sold Shares Worth $4,791,447, According to a Recent SEC Filing | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 51.6 and 41.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+46.81% | 111B | - | ||
+7.32% | 217B | B | ||
+13.83% | 194B | B- | ||
+20.48% | 143B | B- | ||
+3.08% | 64.3B | A- | ||
+14.64% | 52.94B | B+ | ||
+2.72% | 49.53B | B+ | ||
-5.88% | 38.31B | A | ||
+0.25% | 35.22B | - | ||
+22.76% | 30.47B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BSX Stock
- B1SX34 Stock
- Ratings Boston Scientific Corporation